SUPERNUS PHARMACEUTICALS, INC. Debt Securities Available For Sale Excluding Accrued Interest
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Debt Securities Available For Sale Excluding Accrued Interest of $192.11 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-03
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $192.11M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $199.37M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $180.22M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $129.79M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $192.11M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $199.37M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $180.22M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $129.79M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $377.88M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $347.74M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $384.28M 10-K · filed 2026-03-02 |
| 2024-09-30 | $371.54M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $295.10M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $246.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $196.44M 10-K · filed 2025-02-25 |
| 2023-09-30 | $130.33M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $164.43M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $224.28M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $462.11M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $412.23M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $334.73M 10-Q · filed 2022-08-08 |
| 2021-12-31 | $255.41M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |